{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:11:21Z","timestamp":1790806281722,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,1,31]],"date-time":"2002-01-31T00:00:00Z","timestamp":1012435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Interstitial pneumonitis has not been reported as a toxicity of docetaxel. The authors report the presentation and natural history of four patients who developed a severe interstitial pneumonitis after receiving docetaxel.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The hospital and outpatient records of patients treated with docetaxel were reviewed to identify whether any of these patients required an evaluation for respiratory problems.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Four patients developed an interstitial pneumonitis that could be explained only as a toxicity of docetaxel. None had metastatic disease to the lung, and all had normal liver function before receiving chemotherapy. The patients presented with acute dyspnea and fever within 1\u20132 weeks of receiving docetaxel. All developed progressive interstitial infiltrates and respiratory failure that required mechanical ventilation. An exhaustive workup for other causes of pneumonitis was negative. Broad\u2010spectrum antibiotics and corticosteroids were ineffective. Two patients died of complications related to the pulmonary process. The two survivors required ventilatory support for more than 21 days. The clinical and pathologic findings of these patients are presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Interstitial pneumonitis is a rare and potentially fatal complication of docetaxel treatment. Prolonged ventilatory support is appropriate in patients with a favorable prognosis. Cancer 2002;94:847\u201353. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10263<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10263","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T00:51:41Z","timestamp":1030236701000},"page":"847-853","source":"Crossref","is-referenced-by-count":108,"title":["Severe interstitial pneumonitis associated with docetaxel administration"],"prefix":"10.1002","volume":"94","author":[{"given":"William L.","family":"Read","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E.","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,31]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2879"},{"issue":"17","key":"e_1_2_4_3_2","first-page":"14","article-title":"Docetaxel (Taxotere) as monotherapy in the treatment of hormone\u2010refractory prostate cancer: preliminary results","volume":"26","author":"Picus J","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1649"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1853"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1672"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3149"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3426"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321507"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.102"},{"key":"e_1_2_4_11_2","first-page":"1042","article-title":"Paclitaxel hypersensitivity revisited","volume":"14","author":"Essayan DM","year":"1996","journal-title":"J Clin Oncol"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703101205"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.110.1.289"},{"key":"e_1_2_4_14_2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1995.13.2.534","article-title":"Pneumonitis related to treatment with paclitaxel","volume":"13","author":"Goldberg HL","year":"1995","journal-title":"J Clin Oncol"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000011873"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008226416896"},{"key":"e_1_2_4_17_2","first-page":"199","article-title":"[Acute diffuse interstitial pneumopathy following docetaxel (Taxotere). Apropos of 2 cases]","volume":"15","author":"Etienne B","year":"1998","journal-title":"Rev Mal Respir"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2886"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008377819875"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.159"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q"},{"key":"e_1_2_4_22_2","volume-title":"Diffuse lung disorders","author":"Lee\u2010Chong T","year":"1999"},{"key":"e_1_2_4_23_2","first-page":"321","article-title":"Drug\u2010induced pulmonary disease. Part 1. Cytotoxic drugs","volume":"133","author":"Cooper JA","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/139.1.18"},{"key":"e_1_2_4_25_2","first-page":"508","article-title":"Pulmonary toxicity of antineoplastic therapy","volume":"19","author":"Kreisman H","year":"1992","journal-title":"Semin Oncol"},{"key":"e_1_2_4_26_2","unstructured":"Taxotere product information. Strasbourg France: Aventis Pharmaceuticals July2000."},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2181::AID-CNCR2820560907>3.0.CO;2-B"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620000122"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10263","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:10:26Z","timestamp":1760278226000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,31]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1002\/cncr.10263"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10263","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1,31]]}}}